Methods for quantifying il-33
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMichael A. Partridge, Giane Olivera Sumner, Joshua Zylstra
Life of this patent
Estimating the term…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsMichael A. Partridge, Giane Olivera Sumner, Joshua Zylstra
Estimating the term…
Methods and compositions for detecting and quantifying cytokines are provided. The disclosed assays have reduced assay interference relative to commercially available assays and/or a control assay. The interference can be cytokine dependent, cytokine independent, or both. One embodiment provides an IL-33 immunoassay that reduces assay interference caused by endogenous soluble IL-33 binding molecules present in the sample. Exemplary soluble IL-33 binding molecules include, but are not limited to anti-IL-33 antibodies, soluble ST2 receptor, and serum components. In some embodiments a blocking agent is added to the sample to reduce, inhibit, or block IL-33 complexes in the sample from reforming after acid dissociation of the IL-33 complexes in the sample. In one embodiment, the blocking agent and the detection reagent do not compete for binding to IL-33.
A method of decreasing IL-33 assay interference, comprising the steps of:
A method of quantifying interleukin-33 in a serum sample, comprising the steps of:
Dependencies are inferred from the claim text.